^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    IGH translocation

    i
    Other names: IGH, Immunoglobulin Heavy Locus, Immunoglobulin Heavy Polypeptide, Joining Region, Immunglobulin Heavy Chain Variable Region, Immunoglobulin Heavy Diversity Cluster, Immunoglobulin Heavy Variable Cluster, D (Diversity) Region Of Heavy Chains, Immunoglobulin Heavy Diversity Group, Immunoglobulin Heavy Diversity Locus, Immunoglobulin Heavy Joining Cluster, Immunoglobulin Heavy Variable Group, J (Joining) Region Of Heavy Chains, Immunoglobulin Heavy Joining Group, Immunglobulin Heavy Chain, IGH.1@,
    Entrez ID:
    3492
    Related biomarkers:
    Expression
    Mutation
    Fusion
    Others
    11ms
    Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple Myeloma (clinicaltrials.gov)
    P1/2, N=70, Recruiting, Wake Forest University Health Sciences | Active, not recruiting --> Recruiting
    Enrollment open • IO biomarker
    |
    Chr t(4;14) • Chr t(14;16) • IGH translocation
    |
    lenalidomide • carfilzomib • Blenrep (belantamab mafodotin-blmf)
    1year
    Molecular Biomarkers in Prediction of High-Grade Transformation and Outcome in Patients with Follicular Lymphoma: A Comprehensive Systemic Review. (PubMed, Int J Mol Sci)
    The biomarkers included genetic abnormalities, gene expression, microRNAs, markers of B cells/FL tumor cells, markers of the tumor microenvironment, and soluble biomarkers. This comprehensive review provides an overview of the research conducted in the past four decades, underscoring the persistent challenge in risk anticipation of FL patients.
    Review • Journal • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    IGH translocation • BCL2 translocation
    1year
    Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple Myeloma (clinicaltrials.gov)
    P1/2, N=70, Active, not recruiting, Wake Forest University Health Sciences | Trial completion date: Oct 2024 --> Nov 2032 | Trial primary completion date: Oct 2024 --> Apr 2029
    Trial completion date • Trial primary completion date • IO biomarker
    |
    Chr t(4;14) • Chr t(14;16) • IGH translocation
    |
    lenalidomide • carfilzomib • Blenrep (belantamab mafodotin-blmf)
    1year
    Current state of genetic analysis in multiple myeloma and future perspectives (PubMed, Rinsho Ketsueki)
    In addition, the number of ctDNA mutations was identified as a prognostic factor independent of IGH translocations and clinical factors. Here we summarize recent progress in genetic analysis of MM, focusing on clinical relevance.
    Review • Journal
    |
    KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • CRBN (Cereblon)
    |
    TP53 mutation • KRAS mutation • IGH translocation • CRBN mutation
    over1year
    The biological and clinical impact of deletions before and after large chromosomal gains in multiple myeloma. (PubMed, Blood)
    Using multi-omics approaches to investigate their biological impact, we found associations with poor clinical outcome in newly diagnosed patients and profound effects on both oncogene and TSG activity, despite the diploid gene status. Overall, this study provides novel insights into the temporal dynamics of genomic alterations in MM.
    Journal
    |
    IGH (Immunoglobulin Heavy Locus)
    |
    IGH translocation
    over1year
    Case report: Mutation evolution in a patient with TdT positive high grade B cell lymphoma with MYC and BCL2 rearrangements following the treatment of concurrent follicular lymphoma and diffuse large B-cell lymphoma. (PubMed, Discov Oncol)
    This study reports a rare case of TdT positive "double hit" HGBL following the treatment of concurrent FL/DLBCL and highlights the mutation characteristics. Collectively, this study will help enrich the knowledge of TdT positive "double hit" HGBL transformed from FL/DLBCL.
    Journal • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2) • FGFR3 (Fibroblast growth factor receptor 3) • CD20 (Membrane Spanning 4-Domains A1) • KMT2D (Lysine Methyltransferase 2D) • CHEK2 (Checkpoint kinase 2) • CREBBP (CREB binding protein) • BCL7A (BAF Chromatin Remodeling Complex Subunit BCL7A) • CCND3 (Cyclin D3) • MME (Membrane Metalloendopeptidase) • MUC4 (Mucin 4, Cell Surface Associated) • STAT6 (Signal transducer and activator of transcription 6) • ARID5B (AT-Rich Interaction Domain 5B) • DDX3X (DEAD-Box Helicase 3 X-Linked)
    |
    ATM mutation • MYC rearrangement + BCL2 rearrangement • KMT2D mutation • CHEK2 mutation • BCL2 expression • CD20 expression • MYC rearrangement • CD19 expression • BCL2 rearrangement • IGH translocation • BCL2 translocation
    almost2years
    Chromosomal defects in multiple myeloma. (PubMed, Blood Rev)
    Next-generation sequencing is increasingly being used to detect mutations and new FISH techniques such as by flow cytometry are in development and may address some of the current test limitations. Here we review the primary and secondary cytogenetic aberrations in myeloma and discuss the range of techniques available for their assessment.
    Review • Journal
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog)
    |
    MYC translocation • IGH translocation
    almost2years
    Primary central nervous system marginal zone lymphoma. (PubMed, Br J Haematol)
    Short follow-up is a major limitation in reported PCNSMZL cases, which restrains our knowledge on long-term results and iatrogenic sequels. This review was focussed on presentation, differential diagnoses, pathological findings, treatment options and clinical outcomes of PCNSMZL; recommendations for best clinical practice are provided.
    Review • Journal
    |
    CD20 (Membrane Spanning 4-Domains A1) • NOTCH2 (Notch 2) • TNFAIP3 (TNF Alpha Induced Protein 3) • MALT1 (MALT1 Paracaspase)
    |
    IGH translocation
    2years
    Novel identification of t(14;18)(q32;q21)/IGH::MALT1 in chronic lymphocytic leukaemia. (PubMed, Br J Haematol)
    Both cases in this report were associated with lower-risk biological parameters. Thus, FISH testing for MALT1 in cases with unknown IGH translocation partners in the setting of CLL should be implemented in clinical practice to better define such cases.
    Journal
    |
    BCL2 (B-cell CLL/lymphoma 2) • IGH (Immunoglobulin Heavy Locus) • MALT1 (MALT1 Paracaspase) • BCL3 (BCL3 Transcription Coactivator)
    |
    IGH translocation
    2years
    MM-UMA PANEL, AN NGS APPROACH TO DEFINE THE MOLECULAR PROFILE OF MM PATIENTS: INTRA AND INTER LABORATORY VALIDATIONS’ RESULTS (SIE 2023)
    A novel NGS targeted panel was designed and successfully validated, whose main novelty resides in the possibility to call CNAs from off-target reads, that can be used to define MM pts’ genomic risk factors, possibly required in the daily clinical practice. Thanks to AIRC IG2018-22059, AILBolognaODV.
    Clinical • Next-generation sequencing
    |
    KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • TP53 (Tumor protein P53) • NRAS (Neuroblastoma RAS viral oncogene homolog)
    |
    TP53 mutation • KRAS mutation • BRAF mutation • NRAS mutation • ATM mutation • Chr t(11;14) • Chr t(4;14) • Chr t(14;16) • IGH translocation
    2years
    Single Cell Whole Genome Measurement of Genomic Heterogeneity and Clonal Evolution in Multiple Myeloma (ASH 2023)
    We applied DLP to 7 MM patients obtaining 800-1600 single cell whole genomes per patient. All canonical IgH translocations identified by FISH were recovered in the scWGS data. Single cell copy number heterogeneity was observed in all but 1 patient, including heterogeneity affecting known drivers.
    IO biomarker
    |
    TNFRSF17 (TNF Receptor Superfamily Member 17) • SDC1 (Syndecan 1)
    |
    APOBEC mutagenesis • IGH translocation